Aldeyra Therapeutics (ALDX) Tops Q3 EPS by 4c

Aldeyra Therapeutics (NASDAQ: ALDX) reported Q3 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27).

“Our novel RASP inhibitor reproxalap continues to progress toward New Drug Application (NDA) submissions for dry eye disease and allergic conjunctivitis, two of the largest markets in ophthalmology,” stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “Among a number of key clinical milestones planned for the fourth quarter of 2020, we expect to initiate a pivotal Phase 3 objective sign clinical trial of reproxalap for the treatment of dry eye disease, and Phase 2 clinical trials of ADX-629 in COVID-19, atopic asthma, and psoriasis.”

“We concluded the third quarter in a strong financial position, with cash, cash equivalents, and marketable securities of $86.2 million as of September 30,” Dr. Brady continued. “Based on our current operating plans, we expect to have sufficient capital to fund operations through 2022, including NDA submissions for reproxalap in dry eye disease and allergic conjunctivitis, assuming positive clinical trial results and regulatory review.”

For earnings history and earnings-related data on Aldeyra Therapeutics (ALDX) click here.

You May Also Be Interested In

• CalPrivate Bank names Andra Frazier as chief credit officer
• NNN REIT adds two directors amid board succession planning
• BD names Gary Sorsher as chief quality officer, replacing retiree